Delayed microvascular shear adaptation in pulmonary arterial hypertension: Role of platelet endothelial cell adhesion molecule-1 cleavage

American Journal of Respiratory and Critical Care Medicine

Volumn 193, Issue 12, 2016, Pages 1410-1420

  Szulcek, Robert ^a,b   Happe, Chris M ^a   Rol, Nina ^a,b   Fontijn, Ruud D ^b   Dickhoff, Chris ^b   Hartemink, Koen J ^b,h   Grünberg, Katrien ^c,i   Tu, Ly ^d,e   Timens, Wim ^b   Nossent, George D ^f   Paul, Marinus A ^b   Leyen, Thomas A ^b,j   Horrevoets, Anton J ^b   De Man, Frances S ^a   Guignabert, Christophe ^d,e   Yu, Paul B ^g   Vonk Noordegraaf, Anton ^a   Amerongen, Geerten P Van Nieuw ^b   Bogaard, Harm J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Physiology ^*  (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g HARVARD MEDICAL SCHOOL   (United States)

^h ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

ⁱ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^j SANQUIN RESEARCH   (Netherlands)

more..

Author keywords

Endothelial Cell; Microcirculation; Molecular Biology; Pulmonary Arterial Hypertension; Shear Stress

Indexed keywords

CAVEOLIN 1; CD31 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE P60; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR 2;

ANIMAL MODEL; APOPTOSIS; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CELL DAMAGE; CELL FUNCTION; CELL STRUCTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MICROCIRCULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY ARTERIAL ENDOTHELIAL CELL; PULMONARY HYPERTENSION; RAT; SHEAR STRESS; ADULT; ANIMAL; CELL CULTURE; CHILD; DISEASE MODEL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; MALE; METABOLISM; MICROVASCULATURE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PULMONARY ARTERY; VASCULAR REMODELING; WESTERN BLOTTING; YOUNG ADULT;

ADULT; ANIMALS; ANTIGENS, CD31; BLOTTING, WESTERN; CELLS, CULTURED; CHILD; DISEASE MODELS, ANIMAL; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; HYPERTENSION, PULMONARY; MALE; MICROVESSELS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PULMONARY ARTERY; RATS; VASCULAR REMODELING; YOUNG ADULT;

EID: 84988826733     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201506-1231OC     Document Type: Article

References (42)

1. Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62:D34-D41.
2. Voelkel NF, Gomez-Arroyo J, Abbate A, Bogaard HJ, Nicolls MR. Pathobiology of pulmonary arterial hypertension and right ventricular failure. Eur Respir J 2012;40:1555-1565.
3. Botney MD. Role of hemodynamics in pulmonary vascular remodeling: implications for primary pulmonary hypertension. Am J Respir Crit Care Med 1999;159:361-364.
4. Yuan JX, Rubin LJ. Pathogenesis of pulmonary arterial hypertension: The need for multiple hits. Circulation 2005;111:534-538.
5. Rai PR, Cool CD, King JA, Stevens T, Burns N, Winn RA, Kasper M, Voelkel NF. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178:558-564.
6. Guignabert C, Tu L, Le Hiress M, Ricard N, Sattler C, Seferian A, Huertas A, Humbert M, Montani D. Pathogenesis of pulmonary arterial hypertension: lessons from cancer. Eur Respir Rev 2013;22: 543-551.
7. Heath D, Whitaker W. The small pulmonary blood vessels in atrial septal defect. Br Heart J 1957;19:327-332.
8. Rabinovitch M, Bothwell T, Hayakawa BN, Williams WG, Trusler GA, Rowe RD, Olley PM, Cutz E. Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension: A correlation of light with scanning electron microscopy and transmission electron microscopy. Lab Invest 1986; 55:632-653.
9. Dickinson MG, Bartelds B, Borgdorff MA, Berger RM. The role of disturbed blood flow in the development of pulmonary arterial hypertension: lessons from preclinical animal models. Am J Physiol Lung Cell Mol Physiol 2013;305:L1-L14.
10. Sakao S, Taraseviciene-Stewart L, Lee JD, Wood K, Cool CD, Voelkel NF. Initial apoptosis is followed by increased proliferation of apoptosis-resistant endothelial cells. FASEB J 2005;19:1178-1180.
11. Okada K, Tanaka Y, Bernstein M, Zhang W, Patterson GA, Botney MD. Pulmonary hemodynamics modify the rat pulmonary artery response to injury: A neointimal model of pulmonary hypertension. Am J Pathol 1997;151:1019-1025.
12. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001;15:427-438.
13. Nicolls MR, Mizuno S, Taraseviciene-Stewart L, Farkas L, Drake JI, Al Husseini A, Gomez-Arroyo JG, Voelkel NF, Bogaard HJ. New models of pulmonary hypertension based on VEGF receptor blockade-induced endothelial cell apoptosis. Pulm Circ 2012;2: 434-442.
14. Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007;19:2003-2012.
15. Tzima E, Irani-Tehrani M, Kiosses WB, Dejana E, Schultz DA, Engelhardt B, Cao G, DeLisser H, Schwartz MA. A mechanosensory complex that mediates the endothelial cell response to fluid shear stress. Nature 2005;437:426-431.
16. Voelkel NF, Gomez-Arroyo J. The role of vascular endothelial growth factor in pulmonary arterial hypertension: The angiogenesis paradox. Am J Respir Cell Mol Biol 2014;51:474-484.
17. Szulcek R, Fontijn RD, Joemai S, Horrevoets AJ, Vonk-Noordegraaf A, Bogaard HJ, van Nieuw Amerongen GP. The micro-but not macrovascular lung endothelium of pulmonary arterial hypertension patients shows a defective adaptation to high levels of fluid shear stress [abstract]. Am J Respir Crit Care Med 2014; 189:A4807.
18. van der Heijden M, van Nieuw Amerongen GP, van Bezu J, Paul MA, Groeneveld AB, van Hinsbergh VW. Opposing effects of the angiopoietins on the thrombin-induced permeability of human pulmonary microvascular endothelial cells. Plos One 2011;6: e23448.
19. de Raaf MA, Schalij I, Gomez-Arroyo J, Rol N, Happé C, de Man FS, Vonk-Noordegraaf A, Westerhof N, Voelkel NF, Bogaard HJ. SuHx rat model: partly reversible pulmonary hypertension and progressive intima obstruction. Eur Respir J 2014;44:160-168.
20. Taraseviciene-Stewart L, Gera L, Hirth P, Voelkel NF, Tuder RM, Stewart JM. A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model. Can J Physiol Pharmacol 2002;80:269-274.
21. Cicha I, Beronov K, Ramirez EL, Osterode K, Goppelt-Struebe M, Raaz D, Yilmaz A, Daniel WG, Garlichs CD. Shear stress preconditioning modulates endothelial susceptibility to circulating TNF-Alpha and monocytic cell recruitment in a simplified model of arterial bifurcations. Atherosclerosis 2009; 207:93-102.
22. Bakhshi FR, Mao M, Shajahan AN, Piegeler T, Chen Z, Chernaya O, Sharma T, Elliott WM, Szulcek R, Bogaard HJ, et al. Nitrosationdependent caveolin 1 phosphorylation, ubiquitination, and degradation and its association with idiopathic pulmonary arterial hypertension. Pulm Circ 2013;3:816-830.
23. Tu L, Dewachter L, Gore B, Fadel E, Dartevelle P, Simonneau G, Humbert M, Eddahibi S, Guignabert C. Autocrine fibroblast growth factor-2 signaling contributes to altered endothelial phenotype in pulmonary hypertension. Am J Respir Cell Mol Biol 2011;45: 311-322.
24. Upton PD, Morrell NW. TGF-beta and BMPR-II pharmacology: implications for pulmonary vascular diseases. Curr Opin Pharmacol 2009;9:274-280.
25. Privratsky JR, Newman PJ. PECAM-1: regulator of endothelial junctional integrity. Cell Tissue Res 2014;355:607-619.
26. Cool CD, Stewart JS, Werahera P, Miller GJ, Williams RL, Voelkel NF, Tuder RM. Three-dimensional reconstruction of pulmonary arteries in plexiform pulmonary hypertension using cell-specific markers: evidence for a dynamic and heterogeneous process of pulmonary endothelial cell growth. Am J Pathol 1999;155:411-419.
27. Ilan N, Mohsenin A, Cheung L, Madri JA. PECAM-1 shedding during apoptosis generates a membrane-Anchored truncated molecule with unique signaling characteristics. FASEB J 2001;15: 362-372.
28. Diebold I, Hennigs JK, Miyagawa K, Li CG, Nickel NP, Kaschwich M, Cao A, Wang L, Reddy S, Chen PI, et al. BMPR2 preserves mitochondrial function and DNA during reoxygenation to promote endothelial cell survival and reverse pulmonary hypertension. Cell Metab 2015;21:596-608.
29. Bogaard HJ, Mizuno S, Guignabert C, Al Hussaini AA, Farkas D, Ruiter G, Kraskauskas D, Fadel E, Allegood JC, Humbert M, et al. Copper dependence of angioproliferation in pulmonary arterial hypertension in rats and humans. Am J Respir Cell Mol Biol 2012; 46:582-591.
30. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2012;122:4306-4313.
31. Budhiraja R, Tuder RM, Hassoun PM. Endothelial dysfunction in pulmonary hypertension. Circulation 2004;109:159-165.
32. Privratsky JR, Paddock CM, Florey O, Newman DK, Muller WA, Newman PJ. Relative contribution of PECAM-1 adhesion and signaling to the maintenance of vascular integrity. J Cell Sci 2011; 124:1477-1485.
33. Gratzinger D, Canosa S, Engelhardt B, Madri JA. Platelet endothelial cell adhesion molecule-1 modulates endothelial cell motility through the small G-protein Rho. FASEB J 2003;17:1458-1469.
34. Bagi Z, Frangos JA, Yeh JC, White CR, Kaley G, Koller A. PECAM-1 mediates NO-dependent dilation of arterioles to high temporal gradients of shear stress. Arterioscler Thromb Vasc Biol 2005;25: 1590-1595.
35. Woodfin A, Voisin MB, Nourshargh S. PECAM-1: A multi-functional molecule in inflammation and vascular biology. Arterioscler Thromb Vasc Biol 2007;27:2514-2523.
36. Schenkel AR, Chew TW, Chlipala E, Harbord MW, Muller WA. Different susceptibilities of PECAM-deficient mouse strains to spontaneous idiopathic pneumonitis. Exp Mol Pathol 2006;81:23-30.
37. Smith JS, Gorbett D, Mueller J, Perez R, Daniels CJ. Pulmonary hypertension and idiopathic pulmonary fibrosis: A dastardly duo. Am J Med Sci 2013;346:221-225.
38. Postles, A, Clark, AR, Tawhai, MH. Dynamic blood flow and wall shear stress in pulmonary hypertensive disease. Conf Proc IEEE Eng Med Biol Soc 2014;2014:5671-5674.
39. Aird WC. Endothelium in health and disease. Pharmacol Rep 2008;60: 139-143.
40. Deb S, Yun J, Burton N, Omron E, Thurber J, Nathan SD. Reversal of idiopathic pulmonary arterial hypertension and allograft pneumonectomy after single lung transplantation. Chest 2006;130:214-217.
41. Flemming S, Burkard N, Renschler M, Vielmuth F, Meir M, Schick MA, Wunder C, Germer CT, Spindler V, Waschke J, et al. Soluble VEcadherin is involved in endothelial barrier breakdown in systemic inflammation and sepsis. Cardiovasc Res 2015;107:32-44.
42. Pockros PJ, Schiff ER, Shiffman ML, McHutchison JG, Gish RG, Afdhal NH, Makhviladze M, Huyghe M, Hecht D, Oltersdorf T, et al. Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C. Hepatology 2007;46:324-329.